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The extent of alcohol‐related harm a person experiences is dependent on the volume of alcohol they consume and on their pattern of drinking. Worldwide in 2016, 18.2% of the total population aged ≥15 years were reported to engage in heavy episodic drinking (defined as ≥60 g pure alcohol on ≥1 single occasion ≥1 times per month), which has been regarded as the most harmful drinking.[1](#pcn12914-bib-0001){ref-type="ref"} In the USA, the number of high‐risk drinkers was estimated at 29.6 million in 2012--2013.[2](#pcn12914-bib-0002){ref-type="ref"} An epidemiological survey conducted in Japan estimated the number of people with a lifetime diagnosis of alcohol dependence at 1.07 million in 2013, of whom only 13.6% were receiving treatment.[3](#pcn12914-bib-0003){ref-type="ref"} The survey also reported an age‐adjusted rate for hazardous drinking (male, ≥40 g/day; female, ≥20 g/day) of 12.0% in 2003 (male, 19.0%; female, 6.0%) and 9.6% in 2013 (male, 14.4%; female, 5.7%) in Japan.[3](#pcn12914-bib-0003){ref-type="ref"}

Traditionally, abstinence has been regarded as the only appropriate goal in the treatment of alcohol dependence in Japan, but long‐term abstinence retention rates after successful treatment are relatively low (28--32% after 2--3 years and 22--23% after almost 5 years).[4](#pcn12914-bib-0004){ref-type="ref"} Therefore, harm reduction by reducing alcohol consumption, which has been used as a treatment approach in Europe, has now gained recognition in Japan.[5](#pcn12914-bib-0005){ref-type="ref"} The 2018 guideline for the treatment of alcohol dependence in Japan regard abstinence as the primary goal, with reduction of alcohol consumption as an appropriate treatment goal in some patients.[6](#pcn12914-bib-0006){ref-type="ref"}

Nalmefene acts on the opioid system, displaying antagonism at the μ and δ receptors, as well as partial agonism at the κ receptor,[7](#pcn12914-bib-0007){ref-type="ref"} which regulates the reward and reinforcement effects of alcohol.[8](#pcn12914-bib-0008){ref-type="ref"} Nalmefene is currently approved in the European Union, Japan and several other countries for reducing alcohol consumption in alcohol‐dependent patients with a high or very high drinking risk level (DRL) according to World Health Organization (WHO) criteria.

Three studies have been conducted in Europe to evaluate the safety and efficacy of nalmefene 20 mg in reducing alcohol consumption: two 6‐month studies in patients with medium--very high DRL, ESENSE1 and ESENSE2;[9](#pcn12914-bib-0009){ref-type="ref"}, [10](#pcn12914-bib-0010){ref-type="ref"} and a 12‐month study in patients with low--very high DRL, SENSE.[11](#pcn12914-bib-0011){ref-type="ref"} Importantly, in both ESENSE1 and ESENSE2, a high proportion of patients reduced their alcohol intake before randomization, which resulted in a small effect size and a substantial proportion of patients with low and medium DRL at randomization.

The results from these studies led to questions and debate about the efficacy of nalmefene in reducing alcohol consumption. A systematic review conducted by Palpacuer *et al*. concluded that "the value of nalmefene for the treatment of alcohol addiction is not established".[12](#pcn12914-bib-0012){ref-type="ref"} A post‐hoc analysis was performed in the subgroup of patients who continued to have at least high DRL at randomization, which showed statistically significant reductions in heavy drinking days (HDD) and total alcohol consumption (TAC) with nalmefene compared with placebo.[13](#pcn12914-bib-0013){ref-type="ref"} One of the major concerns raised by the European Medicines Agency during the licensing process[14](#pcn12914-bib-0014){ref-type="ref"} and by some critical reviews,[12](#pcn12914-bib-0012){ref-type="ref"} however, was that consistent significant efficacy data were mostly derived from post‐hoc analyses in the subgroup of alcohol‐dependent patients with (very) high DRL.

The present randomized, controlled phase 3 study of nalmefene conducted in Japan was the first prospective clinical study to investigate the efficacy and safety of nalmefene 20 mg, taken as needed, in patients with a high or very high DRL. Two small studies with a lower daily dose of nalmefene (10 mg) have been conducted previously,[15](#pcn12914-bib-0015){ref-type="ref"}, [16](#pcn12914-bib-0016){ref-type="ref"} but those studies reported small non‐significant changes in the number of HDD versus placebo during the study period. In spite of these negative results with daily nalmefene 10 mg, we decided to include a 10 mg arm of nalmefene treatment as needed in the present study based on the hypothesis that the relatively small body size of Japanese patients may influence the results. This was also the first study to evaluate the efficacy of 10 mg nalmefene as needed compared with placebo in alcohol‐dependent patients with a high or very high DRL.

Methods {#pcn12914-sec-0006}
=======

Overview of study design {#pcn12914-sec-0007}
------------------------

This multicenter, randomized, double‐blind, parallel‐group, phase 3 study was conducted at 80 sites in Japan (<http://ClinicalTrials.gov> identifier: NCT02364947). After a 2‐week screening period, patients received 24 weeks of double‐blind treatment, followed by 4 weeks of follow up (Fig. [S1](#pcn12914-supitem-0001){ref-type="supplementary-material"}). During the follow‐up period, only safety‐related information was collected and no drugs were given. Patients were invited to participate in the study via newspaper and online advertisements, as well as through the physician\'s clinic. All responding patients were screened for eligibility, and those meeting the study criteria were randomly assigned (4:3:4) using an interactive Web response system to as‐needed use of either nalmefene 20 mg, 10 mg (as an anhydride of nalmefene hydrochloride), or matched placebo tablets. Randomization was not stratified by patient characteristics or alcohol consumption status. Patients were instructed to take one tablet on days they perceived themselves to be at risk of drinking alcohol, preferably 1--2 h before they were likely to start drinking, but otherwise as soon as alcohol consumption began. The investigator and patients remained masked to treatment allocation throughout the study period.

All enrolled patients participated in a psychosocial support program that was developed based on the BRENDA model,[17](#pcn12914-bib-0017){ref-type="ref"}, [18](#pcn12914-bib-0018){ref-type="ref"} and aimed to help patients change their drinking behavior and maximize adherence to treatment. This program began at randomization and was performed at all site visits and up to the end of the study treatment by pre‐trained investigators. At each visit, patients were allowed to continue with subsequent treatment with nalmefene or placebo only after attending the psychosocial support program. The main components of this program included: psychosocial evaluation of the patient, feedback to patients about the outcomes of the assessment, empathic and non‐judgmental consideration of the patient\'s situation, collaborative identification of patient needs, advising patients on ways to meet the identified needs, and assessing patient response to the advice and adjusting the therapy accordingly to achieve best patient care.

Alcohol consumption was estimated using the timeline follow‐back method.[19](#pcn12914-bib-0019){ref-type="ref"} Measurements, assessments, and evaluations used during the study are summarized in Table [S1](#pcn12914-supitem-0001){ref-type="supplementary-material"}.

This study was conducted in accordance with the protocol, the ethics principles outlined in the Declaration of Helsinki, and the International Council for Harmonization\'s Harmonized Tripartite Guideline for Good Clinical Practice. The study protocol was approved by the institutional review board at each participating center before the study initiation and no changes were made to the protocol during the study. All patients provided written informed consent before entering the study.

Participants {#pcn12914-sec-0008}
------------

Men and women ≥20 years of age were eligible to participate in the study if they had a primary diagnosis of alcohol dependence according to the *Diagnostic and Statistical Manual of Mental Disorders*, 4th Edition, text revision (DSM‐IV‐TR), and assessed using the Mini‐International Neuropsychiatric Interview, had an exhaled alcohol concentration \<0.1 mg/L at screening visit, and met the WHO criteria for a high or very high DRL (consumption of \>60 g of alcohol per day for men and \>40 g of alcohol per day for women) at both screening and randomization visits.[20](#pcn12914-bib-0020){ref-type="ref"} The main exclusion criterion was \<6 HDD or \>5 consecutive days of abstinence in the 4 weeks before the screening visit. Patients were also excluded if they had a current diagnosis of an axis I disorder other than alcohol, nicotine, and caffeine dependence according to DSM‐IV‐TR, and if they had a score ≥10 on the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA‐Ar) scale at screening or randomization. The list of prohibited concomitant medications is given in Table [S2](#pcn12914-supitem-0001){ref-type="supplementary-material"}, and a complete list of inclusion and exclusion criteria is given in Table [S3](#pcn12914-supitem-0001){ref-type="supplementary-material"}.

Outcomes {#pcn12914-sec-0009}
--------

The primary endpoint of this study was the change in the number of HDD in 1 month (4 weeks or 28 consecutive days) from baseline to week 12. An HDD was defined as a day with alcohol consumption \>60 g for men and \>40 g for women.[21](#pcn12914-bib-0021){ref-type="ref"} The key secondary endpoint was the change in TAC from baseline to week 12 based on the average daily alcohol consumption in g/day. Alcohol consumption was converted from number of standard drinks to grams by multiplying by 10, in accordance with WHO guidelines for estimating alcohol consumption‐related harm.[20](#pcn12914-bib-0020){ref-type="ref"} Baseline values for the number of HDD and TAC were calculated from the 4‐week data prior to the screening visit, and DRL was calculated from TAC at randomization. Post‐baseline HDD and TAC were calculated for every 4‐week period.

Other secondary endpoints included: the proportion of patients with a downward shift in DRL of two categories or more (response shift DRL, RSDRL); the proportion of patients with low or lower DRL (response low DRL, RLDRL); the proportion of patients with a 70% decrease in TAC (TAC70); the proportion of patients with ≤4 HDD (HDD response); Clinical Global Impression--Severity of Illness (CGI‐S) score; Clinical Global Impression--Global Improvement (CGI‐I) score; 36‐item Short‐form Health Survey (SF‐36) score; EuroQol 5 Dimension (EQ‐5D) utility score including visual analogue scale (VAS) for health status; Alcohol Quality of Life Scale (AQoLs); serum γ‐glutamyltransferase (γ‐GT); and serum alanine aminotransferase (ALT). All secondary endpoints were evaluated using the data obtained at weeks 12 and 24, except for CGI‐S and CGI‐I, for which data obtained by the investigators or sub‐investigators at weeks 1, 2, 4, 8, 16, and 20 were used.

The rate of nalmefene use during the study was calculated by determining the number of days patients received the drug during the treatment period.

Safety data collected during the study included treatment‐emergent adverse events (TEAE), clinical laboratory tests, vital signs, bodyweight, 12‐lead electrocardiogram (ECG), and Columbia‐Suicide Severity Rating Scale (C‐SSRS). Patients were asked to return for a safety follow‐up visit 4 weeks after completing or withdrawing from the study. TEAE were evaluated at week 24 and recorded using MedDRA/J Version 19.0.

Statistical analysis {#pcn12914-sec-0010}
--------------------

A calculation based on unpublished data from the ESENSE1 and ESENSE2 studies indicated that, in patients with a high or very high DRL treated with nalmefene 20 mg for 12 weeks, the number of HDD was reduced by 2.66 days/month relative to placebo (SD, 9.37 days). Assuming the same difference in effect and rate of dropout, a sample of 240 patients in the nalmefene 20 mg and placebo groups would be required to detect a difference in the number of HDD between these treatments with a power of 87.4% and a two‐sided significance level of 5%. The statistical power of the 10 mg group was calculated using the same method as the statistical power of the 20 mg group, assuming a difference of 2.66 between the 10 mg group and the placebo group with an SD of 9.37. As a result, the power of detecting a difference between 10 mg and placebo was 81.9%, with 180 patients in the nalmefene 10 mg arm, and the probability of both doses showing significance was around 75%.

Efficacy analyses were conducted on the full analysis set, which included all patients who had data on the number of HDD at baseline and at ≥1 time point after initiation of the study drug. Safety analyses included all randomized patients who received ≥1 dose of the study medication.

Mixed model for repeated measures (MMRM) with fixed effect of treatment, sex, time point (week 4, 8, 12, 16, 20, and 24), treatment × time point interaction, baseline value, and baseline value × time point interaction with an unstructured variance--covariance matrix structure was used to analyze the change from baseline in HDD and TAC. In this study, the number of HDD (the primary endpoint) was measured first, followed by TAC (key secondary endpoint). Efficacy of the doses (change from baseline in the number of HDD vs placebo) was assessed using a closed testing procedure. The 20 mg dose was tested at a 5% level of significance and only if significant, the testing would proceed to the 10 mg dose. Multiplicity was not considered for TAC.

Sensitivity analyses were also conducted to evaluate the robustness of the main analyses. The same MMRM analyses were used with either (i) follow‐up data for patients who discontinued treatment during the treatment period, or (ii) multiple imputation assuming that patients who withdrew from the study would behave in the future in the same way as patients in the placebo group with a similar past.[22](#pcn12914-bib-0022){ref-type="ref"}

For RSDRL and RLDRL, differences between the treatment and placebo groups were assessed using the Cochran‐Mantel‐Haenszel test, stratified by sex and baseline DRL. An MMRM approach was used to analyze the CGI‐I, CGI‐S, SF‐36, EQ‐5D, and AQoLs scores. For MMRM analyses, γ‐GT and ALT were transformed logarithmically.

A post‐hoc analysis of HDD data at weeks 12 and 24 using MMRM was performed to compare nalmefene 20 mg and nalmefene 10 mg. Differences were assessed using the Wald test. The study completion rate in each group compared with placebo was analyzed using the Pearson\'s chi‐squared test. Also, the proportion of days with medication intake in each group during the study was compared using the Student *t*‐test.

SAS version 9.4 (SAS Institute, Tokyo, Japan) was used for all statistical calculations.

Results {#pcn12914-sec-0011}
=======

Patient disposition and characteristics {#pcn12914-sec-0012}
---------------------------------------

Between 9 February 2015 and 30 July 2016, 867 patients were enrolled in the study and 678 were randomized. One patient who was randomized withdrew consent before starting the study medication; therefore, 677 patients received the study medication: nalmefene 20 mg (*n* = 248), nalmefene 10 mg (*n* = 184), or placebo (*n* = 245; Fig. [1](#pcn12914-fig-0001){ref-type="fig"}, Doc.[S1](#pcn12914-supitem-0001){ref-type="supplementary-material"}). Of these, 80.8% completed the study; the treatment completion rates were 76.2% (*P* = 0.0001 vs placebo), 75.5% (*P* = 0.0001 vs placebo), and 89.4% in the nalmefene 20 mg, nalmefene 10 mg, and placebo groups, respectively.

![Patient selection. Safety analysis set (SAS) included patients who received at least one dose of placebo or nalmefene during the study period, *n* = 677. Full analysis set (FAS) included patients from the SAS who had baseline data available along with at least one heavy drinking days during the study period. Six patients in the nalmefene 20 mg group, four in the nalmefene 10 mg group and one patient in the placebo group were not included in the FAS.](PCN-73-697-g001){#pcn12914-fig-0001}

The baseline characteristics and demographics were similar between all three treatment groups (Table [1](#pcn12914-tbl-0001){ref-type="table"}). The mean age was 48.7 years and the mean age at onset of the drinking problem was 36.9 years. In the total study group, mean TAC was 94.58 ± 42.79 g/day and the mean number of HDD were 22.99 ± 6.32 days/month; the majority of patients included in the study were treatment naïve (97.4%), with only 2.6% of patients receiving previous treatment.

###### 

Baseline characteristics of the full analysis set population

                                                                   Nalmefene     Placebo (*n* = 244) Mean ± SD or *n* (%)   Total (*n* = 666) Mean ± SD or *n* (%)                  
  ------------------------------------------- ----------------- --------------- ------------------------------------------ ---------------------------------------- --------------- ---------------
  Sex                                         Male                170 (70.2)                    134 (74.4)                                304 (72.0)                  154 (63.1)      458 (68.8)
  Age (years)                                                     48.9 ± 12.2                  49.2 ± 11.9                               49.0 ± 12.1                  48.1 ± 11.4     48.7 ± 11.8
  BMI (kg/m^2^)                                                  23.04 ± 3.24                  23.32 ± 3.47                              23.16 ± 3.34                23.11 ± 3.40    23.14 ± 3.36
  Smoking history                             Never                60 (24.8)                    45 (25.0)                                 105 (24.9)                   57 (23.4)      162 (24.3)
  Smoking status                              Current smokers      66 (27.3)                    41 (22.8)                                 107 (25.4)                   86 (35.2)      193 (29.0)
  Drug abuse history                          No                  242 (100.0)                  180 (100.0)                               422 (100.0)                  244 (100.0)     666 (100.0)
  Marital status                              Married             169 (69.8)                    125 (69.4)                                294 (69.7)                  160 (65.6)      454 (68.2)
  Employment status                           Employed            198 (81.8)                    150 (83.3)                                348 (82.5)                  199 (81.6)      547 (82.1)
  CIWA‐Ar                                                          0.5 ± 1.3                    0.5 ± 1.2                                 0.5 ± 1.2                    0.5 ± 1.2       0.5 ± 1.2
  SF‐36 PCS                                                       52.1 ± 8.2                    52.7 ± 7.8                                52.3 ± 8.0                  52.1 ± 8.3      52.2 ± 8.1
  SF‐36 MCS                                                       51.7 ± 8.5                    51.4 ± 8.1                                51.6 ± 8.3                  51.7 ± 8.3      51.6 ± 8.3
  Age at onset of drinking problem (years)                        37.4 ± 13.7                  37.6 ± 12.4                               37.5 ± 13.2                  36.0 ± 12.0     36.9 ± 12.7
  WHO Drinking risk level                     Very high           107 (44.2)                    87 (48.3)                                 194 (46.0)                  116 (47.5)      310 (46.5)
                                              High                135 (55.8)                    93 (51.7)                                 228 (54.0)                  127 (52.0)      355 (53.3)
                                              Medium                   0                            0                                         0                         1 (0.4)         1 (0.2)
                                              Low                      0                            0                                         0                            0               0
  HDD (days/month)                                               22.64 ± 6.37                  23.49 ± 6.07                              23.00 ± 6.25                22.97 ± 6.44    22.99 ± 6.32
  TAC (g/day)                                                    93.07 ± 37.45                95.93 ± 41.10                             94.29 ± 39.03                95.08 ± 48.70   94.58 ± 42.79
  CGI‐S                                                           3.38 ± 1.06                  3.48 ± 1.15                               3.42 ± 1.09                  3.45 ± 1.09     3.43 ± 1.09
  γ‐GT (IU/L)                                                    84.7 ± 105.4                  80.7 ± 103.8                              83.0 ± 104.6                 70.7 ± 78.7     78.5 ± 96.1
  ALT (IU/L)                                                      24.3 ± 14.2                  24.5 ± 14.9                               24.4 ± 14.5                  23.3 ± 14.8     24.0 ± 14.6
  Previously treated for alcohol dependence                         5 (2.1)                      3 (1.7)                                   8 (1.9)                      9 (3.7)        17 (2.6)
  Previously treated for alcohol withdrawal                            0                            0                                         0                            0               0
  Family history of alcohol problems                               31 (12.8)                    26 (14.4)                                 57 (13.5)                    39 (16.0)       96 (14.4)

ALT, alanine aminotransferase; BMI, body mass index; CGI--S, Clinical Global Impression--Severity of illness; CIWA‐Ar, Clinical Institute Withdrawal Assessment for Alcohol (revised version); γ‐GT, γ‐glutamyltransferase; HDD, heavy drinking days; MCS, mental component summary; PCS, physical component summary; WHO, World Health Organization; SD, standard deviation; SF‐36, 36‐item Short‐form Health Survey; TAC, total alcohol consumption.

Patients in the nalmefene 20 mg, 10 mg, and placebo groups took medication on a mean of 70.6% (*P* \< 0.0001 vs placebo, *P* = 0.0829 vs 10 mg), 75.1% (*P* \< 0.0001 vs placebo), and 87.0% of days, respectively during the study.

Primary endpoint and major efficacy outcomes {#pcn12914-sec-0013}
--------------------------------------------

After 12 weeks of treatment, the mean number of HDD was reduced in all three treatment groups (Table [2](#pcn12914-tbl-0002){ref-type="table"}). In both nalmefene treatment groups, statistically significant reductions in the number of HDD were observed relative to the placebo group at week 12. These reductions from baseline were observed from week 4, and the significant effect was sustained throughout the 24‐week treatment period (Table [2](#pcn12914-tbl-0002){ref-type="table"}; Fig. [2](#pcn12914-fig-0002){ref-type="fig"}). The results were consistent with the two sensitivity analyses, including follow‐up data for patients who discontinued treatment during the treatment period (Table [S4](#pcn12914-supitem-0001){ref-type="supplementary-material"}) and using multiple imputation analysis based on the placebo group (Table [S5](#pcn12914-supitem-0001){ref-type="supplementary-material"}).

###### 

Mean change in HDD and TAC in the full analysis set

                                                     Value       Adjusted change from baseline^†^                                  
  ------------------ ---------- --------------- --------------- ---------------------------------- ----------------- ---------- -- --
  HDD (days/month)   Baseline   Placebo               244                  22.97 ± 6.44                                            
  Nalmefene 20 mg    242        22.64 ± 6.37                                                                                       
  Nalmefene 10 mg    180        23.49 ± 6.07                                                                                       
  Week 12            Placebo    234              15.56 ± 9.74              −7.91 ± 0.61                                            
  Nalmefene 20 mg    206        11.42 ± 9.74     −12.25 ± 0.64             −4.34 ± 0.87             −6.05 to −2.62    \<0.0001     
  Nalmefene 10 mg    154        12.04 ± 10.27    −12.09 ± 0.74             −4.18 ± 0.95             −6.05 to −2.32    \<0.0001     
  Week 24            Placebo    222              14.03 ± 10.20             −9.33 ± 0.63                                            
  Nalmefene 20 mg    189        10.62 ± 9.43     −13.25 ± 0.66             −3.92 ± 0.90             −5.69 to −2.16    \<0.0001     
  Nalmefene 10 mg    141        9.82 ± 9.97      −13.88 ± 0.77             −4.54 ± 0.98             −6.46 to −2.63    \<0.0001     
  TAC (g/day)        Baseline   Placebo               244                 95.08 ± 48.70                                            
  Nalmefene 20 mg    242        93.07 ± 37.45                                                                                      
  Nalmefene 10 mg    180        95.93 ± 41.10                                                                                      
  Week 12            Placebo    234              65.39 ± 32.72            −32.43 ± 1.91                                            
  Nalmefene 20 mg    206        54.51 ± 34.88    −44.90 ± 2.01            −12.47 ± 2.72             −17.81 to −7.13   \<0.0001     
  Nalmefene 10 mg    154        55.15 ± 34.46    −45.36 ± 2.32            −12.94 ± 2.95             −18.72 to −7.15   \<0.0001     
  Week 24            Placebo    222              59.28 ± 31.50            −38.28 ± 1.99                                            
  Nalmefene 20 mg    189        51.38 ± 33.82    −49.43 ± 2.13            −11.15 ± 2.86             −16.77 to −5.53    0.0001      
  Nalmefene 10 mg    141        48.74 ± 33.32    −49.55 ± 2.45            −11.27 ± 3.11             −17.37 to −5.17    0.0003      

Derived from a mixed model for repeated measures approach.

CI, confidence interval; HDD, heavy drinking days; LS, least squares; SD, standard deviation; SE, standard error; TAC, total alcohol consumption.

![Change from baseline in the number of heavy drinking days (HDD) in study participants by treatment group (mixed model for repeated measures; MMRM, with observed cases). (![](PCN-73-697-g004.jpg "image")) Placebo; (![](PCN-73-697-g005.jpg "image")) nalmefene 20 mg; (![](PCN-73-697-g006.jpg "image")) nalmefene 10 mg. Data given as least squares mean ± SE. \**P* \< 0.05 placebo vs nalmefene 20 mg; †*P* \< 0.05 placebo vs nalmefene 10 mg.](PCN-73-697-g002){#pcn12914-fig-0002}

On post‐hoc analysis comparing nalmefene 10 mg and 20 mg, HDD reductions with nalmefene 10 mg at week 12 (*P* = 0.8738) and at week 24 (*P* = 0.5314) were similar to those observed with nalmefene 20 mg.

Secondary endpoints {#pcn12914-sec-0014}
-------------------

Mean TAC at baseline was similar in all treatment groups (Table [2](#pcn12914-tbl-0002){ref-type="table"}). After 12 weeks of treatment, mean TAC decreased in all treatment groups. In both nalmefene treatment groups, a greater reduction in TAC was observed at week 12 relative to the placebo group. These reductions in TAC were observed from week 4 and the significant effect was sustained throughout the 24‐week treatment period (Table [2](#pcn12914-tbl-0002){ref-type="table"}; Fig. [3](#pcn12914-fig-0003){ref-type="fig"}). Similar results were observed in the two sensitivity analyses (Tables [S2,S5](#pcn12914-supitem-0001){ref-type="supplementary-material"}).

![Change from baseline in total alcohol consumption (TAC) in study participants by treatment group (mixed model for repeated measures; MMRM, with observed cases). (![](PCN-73-697-g007.jpg "image")) Placebo; (![](PCN-73-697-g008.jpg "image")) nalmefene 20 mg; (![](PCN-73-697-g009.jpg "image")) nalmefene 10 mg. Data given as least squares mean ± SE. \**P* \< 0.05 placebo vs nalmefene 20 mg; †*P* \< 0.05 placebo vs nalmefene.](PCN-73-697-g003){#pcn12914-fig-0003}

The proportions of patients with RSDRL, RLDRL, TAC70, and HDD response were higher with nalmefene 20 mg and 10 mg than with placebo (Table [3](#pcn12914-tbl-0003){ref-type="table"}). The number needed to treat (NNT) to achieve a response ranged from 4.5 to 12.5, depending on the response criterion and the nalmefene dose (Table [3](#pcn12914-tbl-0003){ref-type="table"}). CGI‐S and CGI‐I were improved with nalmefene 20 mg and 10 mg compared with placebo at all time points during double‐blind treatment (Figs [S2, S3](#pcn12914-supitem-0001){ref-type="supplementary-material"}). Serum γ‐GT, ALT, and total AQoLs scores improved in patients who received nalmefene 20 mg or 10 mg compared with placebo recipients (Tables [S6,S7](#pcn12914-supitem-0001){ref-type="supplementary-material"}).

###### 

Secondary endpoints

                                                             Responders           CMH test^†^         
  ------------------- --------- ----------- ----------- --------------------- -------------------- -- --
  RSDRL               Week 12   Placebo         234           47 (20.1)                               
  Nalmefene 20 mg     206       85 (41.3)    \<0.0001    22.0 (13.6 to 30.4)    4.5 (3.3 to 7.4)      
  Nalmefene 10 mg     154       55 (35.7)     0.0007     15.7 (6.5 to 25.0)    6.4 (4.0 to 15.4)      
  Week 24             Placebo   222          61 (27.5)                                                
  Nalmefene 20 mg     189       84 (44.4)     0.0002     18.0 (8.8 to 27.2)    5.6 (3.7 to 11.4)      
  Nalmefene 10 mg     141       67 (47.5)     0.0001     20.6 (10.4 to 30.8)    4.9 (3.2 to 9.6)      
  RLDRL               Week 12   Placebo         234           25 (10.7)                               
  Nalmefene 20 mg     206       61 (29.6)    \<0.0001    17.8 (10.5 to 25.1)    5.6 (4.0 to 9.5)      
  Nalmefene 10 mg     154       39 (25.3)     0.0002     14.3 (6.4 to 22.2)    7.0 (4.5 to 15.6)      
  Week 24             Placebo   222          39 (17.6)                                                
  Nalmefene 20 mg     189       56 (29.6)     0.0079     11.0 (2.9 to 19 1)    9.1 (5.2 to 34.5)      
  Nalmefene 10 mg     141       46 (32.6)     0.0010     14.8 (5.8 to 23.9)    6.8 (4.2 to 17.2)      
  TAC70               Week 12   Placebo         234           20 (8.5)                                
  Nalmefene 20 mg     206       37 (18.0)     0.0022      9.9 (3.5 to 16.3)    10.1 (6.1 to 28.6)     
  Nalmefene 10 mg     154       30 (19.5)     0.0016     11.1 (3.8 to 18.3)    9.0 (5.5 to 26.3)      
  Week 24             Placebo   222          24 (10.8)                                                
  Nalmefene 20 mg     189       45 (23.8)     0.0003     13.6 (6.2 to 20.9)    7.4 (4.8 to 16.1)      
  Nalmefene 10 mg     141       33 (23.4)     0.0013     12.8 (4.6 to 21.0)    7.8 (4.8 to 21.7)      
  HDD response rate   Week 12   Placebo         234           45 (19.2)                               
  Nalmefene 20 mg     206       72 (35.0)     0.0002     15.2 (7.1 to 23.3)    6.6 (4.3 to 14.1)      
  Nalmefene 10 mg     154       56 (36.4)     0.0001     17.9 (8.9 to 26.9)    5.6 (3.7 to 11.2)      
                      Week 24   Placebo         222           56 (25.2)                               
  Nalmefene 20 mg     189       64 (33.9)     0.0724     8.0 (−0.7 to 16.7)     12.5 (6.0 to NA)      
  Nalmefene 10 mg     141       62 (44.0)     0.0001     19.6 (9.9 to 29.2)    5.1 (3.4 to 10.1)      

Adjusting for sex and baseline DRL.

CI, confidence interval; CMH, Cochran‐Mantel‐Haenszel; diff, difference; DRL, drinking risk level; HDD response rate; heavy drinking days ≤4 days; NA, not available; NNT, number needed to treat; RLDRL, response low drinking risk level; RSDRL, response shift drinking risk level; TAC70, 70% decrease in total alcohol consumption.

The physical component and mental component summaries (MCS) in SF‐36, EQ‐5D score for health status, and VAS were similar in all treatment groups (Table [S8](#pcn12914-supitem-0001){ref-type="supplementary-material"}).

Safety {#pcn12914-sec-0015}
------

The incidences of any AE and of those that led to discontinuation were higher in the groups receiving nalmefene 20 mg and 10 mg than in the placebo group (Table [4](#pcn12914-tbl-0004){ref-type="table"}). The primary reasons for discontinuation in all treatment groups were AE. AE that occurred in ≥5% of patients in either the nalmefene 20 mg or 10 mg group and at least twice as often as in the placebo group were nausea, dizziness, somnolence, vomiting, malaise, insomnia, decreased appetite, constipation, and palpitations. Most AE were mild or moderate in severity. Compared with the 20 mg dose, the 10 mg dose of nalmefene was associated with ≥5% lower rates of dizziness (20.6% vs 10.9%), malaise (9.7% vs 3.8%), somnolence (15.7% vs 9.8%), and vomiting (13.7% vs 8.7%). The rates of other AE were generally similar between the two doses. Time to first onset and duration of AE that occurred in ≥5% of patients are presented in Table [S9](#pcn12914-supitem-0001){ref-type="supplementary-material"}.

###### 

Adverse events in the safety analysis set

                                                Nalmefene                             
  -------------------------------------------- ------------ ------------ ------------ ------------
  Any TEAE^†^                                   218 (87.9)   156 (84.8)   374 (86.6)   194 (79.2)
  TEAE reported in ≥5% of patients                                                    
  Constipation                                   13 (5.2)     8 (4.3)      21 (4.9)     2 (0.8)
  Dizziness                                     51 (20.6)    20 (10.9)    71 (16.4)     10 (4.1)
  Headache                                       24 (9.7)    21 (11.4)    45 (10.4)     20 (8.2)
  Insomnia                                       20 (8.1)     15 (8.2)     35 (8.1)     2 (0.8)
  Malaise                                        24 (9.7)     7 (3.8)      31 (7.2)     8 (3.3)
  Nasopharyngitis                               54 (21.8)    40 (21.7)    94 (21.8)    91 (37.1)
  Nausea                                        79 (31.9)    58 (31.5)    137 (31.7)    15 (6.1)
  Palpitations                                   13 (5.2)     7 (3.8)      20 (4.6)     2 (0.8)
  Somnolence                                    39 (15.7)     18 (9.8)    57 (13.2)     17 (6.9)
  Vomiting                                      34 (13.7)     16 (8.7)    50 (11.6)     5 (2.0)
  Decreased appetite                             13 (5.2)     11 (6.0)     24 (5.6)     3 (1.2)
  TEAE leading to dropout in ≥2% of patients                                          
  Nausea                                         21 (8.5)     12 (6.5)     33 (7.6)     0 (0.0)
  Dizziness                                      16 (6.5)     9 (4.9)      25 (5.8)     1 (0.4)
  Vomiting                                       10 (4.0)     5 (2.7)      15 (3.5)     0 (0.0)
  Headache                                       9 (3.6)      7 (3.8)      16 (3.7)     1 (0.4)
  Insomnia                                       5 (2.0)      5 (2.7)      10 (2.3)     0 (0.0)
  Nasopharyngitis                                0 (0.0)      1 (0.5)      1 (0.2)      7 (2.9)
  Decreased appetite                             1 (0.4)      4 (2.2)      5 (1.2)      0 (0.0)
  Palpitations                                   5 (2.0)      1 (0.5)      6 (1.4)      0 (0.0)
  Serious AE^‡^                                  2 (0.8)      2 (1.1)      4 (0.9)      2 (0.8)

In the 24‐week treatment period.

In the entire study period.

AE, adverse event, TEAE, treatment‐emergent adverse event.

Nausea, dizziness, vomiting, headache, insomnia, palpitations, and decreased appetite were the most common AE that led to discontinuation in ≥2% of patients for either the 20 mg dose or 10 mg dose (Table [4](#pcn12914-tbl-0004){ref-type="table"}).

Serious AE (SAE) were reported in all treatment groups, occurring in two patients (0.8%), two patients (1.1%), and two patients (0.8%) in the nalmefene 20 mg, nalmefene 10 mg, and placebo groups, respectively. SAE included chronic hepatitis and gastroenteritis in the nalmefene 20 mg group, femur fracture, spinal compression fracture (both occurred in the same patient), and death in the nalmefene 10 mg group, and anastomotic ulcer hemorrhage, and alcoholism in the placebo group. Chronic hepatitis and anastomotic ulcer hemorrhage were considered related to the study medication, while other SAE were not. One death occurred during the course of the study: a male patient in the nalmefene 10 mg group died 168 days after receiving the first dose of treatment. The cause of death was unknown and its association with the treatment could not be ruled out.

There were no clinically significant laboratory findings and no clinically relevant changes or differences between treatment groups in vital signs, weight, or ECG parameters. Two patients in the group receiving 20 mg nalmefene, two in the 10 mg nalmefene group and three in the placebo group had suicidal ideation according to the C‐SSRS evaluation, but none showed any suicidal behavior.

Discussion {#pcn12914-sec-0016}
==========

In this study, nalmefene 20 mg significantly reduced alcohol consumption, as measured by the number of HDD and TAC, relative to placebo over the period of 24 weeks. The robustness of these findings was consistent in two sensitivity analyses, including follow‐up data for patients who discontinued treatment and using multiple imputation analysis based on the placebo group. To our knowledge, this is the first prospective, randomized controlled clinical study to show the efficacy of nalmefene 20 mg in reducing the number of HDD and TAC after 12 and 24 weeks of treatment in Japanese patients with a high or very high DRL.

Several phase 3 trials of nalmefene conducted in non‐Japanese patients (ESENSE1, ESENSE 2, SENSE) have shown that nalmefene treatment was associated with a significant decrease from baseline in the number of HDD at week 12, the effect being sustained for up to 24 weeks.[9](#pcn12914-bib-0009){ref-type="ref"}, [10](#pcn12914-bib-0010){ref-type="ref"}, [11](#pcn12914-bib-0011){ref-type="ref"} The number of patients withdrawing from these studies, however, increased after week 12. Based on these data, the primary endpoint was assessed at week 12 in the present study, with a total treatment period of 24 weeks to confirm the sustained decrease in alcohol consumption with nalmefene in alcohol‐dependent Japanese patients with a high or very high DRL.

In the present study, a lower dose of nalmefene (10 mg) was also effective in reducing potentially harmful drinking as indicated by the number of HDD and TAC compared with placebo. On post‐hoc analysis nalmefene 10 mg had similar efficacy to that of the 20 mg dose in reducing the number of HDD at weeks 12 and 24. The number and type of TEAE that occurred in patients treated with nalmefene in the present study are consistent with those of previous studies.[9](#pcn12914-bib-0009){ref-type="ref"}, [10](#pcn12914-bib-0010){ref-type="ref"}, [11](#pcn12914-bib-0011){ref-type="ref"} The incidence of nausea, which was the most frequently observed AE, was similar between the two groups. Some other AE, however, including dizziness, somnolence and vomiting were less frequent in the 10 mg group compared with 20 mg nalmefene in this study. This suggests that nalmefene 10 mg can be a therapeutic option in the treatment of alcohol dependence with similar efficacy and a lower incidence of AE.

There has been a debate regarding the approval of nalmefene in patients with high or very high DRL not being based on evidence from clinical trials, given that the majority of data on the efficacy of nalmefene in this subgroup of patients is based on post‐hoc analysis.[23](#pcn12914-bib-0023){ref-type="ref"} The present results confirm the efficacy of nalmefene in the reduction of alcohol consumption using a prospective, randomized, controlled study design and, therefore, provide important information that can help advance this discussion.

The main difference between the design of this study and other studies conducted in Europe[9](#pcn12914-bib-0009){ref-type="ref"}, [10](#pcn12914-bib-0010){ref-type="ref"} was that only patients with a high or very high DRL were included in the present study. With the exception of DRL, the characteristics of patients who participated in the present study were generally similar to those of patients who took part in previous studies of nalmefene.[9](#pcn12914-bib-0009){ref-type="ref"}, [10](#pcn12914-bib-0010){ref-type="ref"}, [11](#pcn12914-bib-0011){ref-type="ref"} There were several distinguishing characteristics, however, of the present patients. In the present study, only 2.6% of patients had previously undergone treatment for alcohol dependence, compared with 29.8% of patients in the ESENSE1,[9](#pcn12914-bib-0009){ref-type="ref"} 40.3% of patients in ESENSE2,[10](#pcn12914-bib-0010){ref-type="ref"} and 34.4% of patients in the SENSE study.[11](#pcn12914-bib-0011){ref-type="ref"} Additionally, baseline CIWA‐Ar scores in the nalmefene 20 mg, 10 mg, and placebo groups were low,[24](#pcn12914-bib-0024){ref-type="ref"} and baseline SF‐46 MCS scores of this study were higher than baseline MCS scores in ESENSE1 and ESENSE2.[23](#pcn12914-bib-0023){ref-type="ref"} Furthermore, 68.2% of patients in the present study were married or living with partners, and 82.1% were employed, which indicated a relatively high degree of social and emotional support and functioning. Patients in this study were also different from the patients in another study focused on alcohol abstinence conducted in Japan[25](#pcn12914-bib-0025){ref-type="ref"} in terms of age distribution, with the present patients being younger (median age \< 50 years).

In the present study, the rates of treatment completion and study drug use were both higher than in the previous European studies of nalmefene. In particular, the treatment completion rates observed at week 24 in this study (89%, 76%, 76% for placebo, nalmefene 10 mg and 20 mg, respectively) were considerably higher than completion rates reported in previous studies with nalmefene (46% for nalmefene 20 mg and 68% for placebo in ESENSE1, and 57% and 61% in ESENSE2) or with other pharmacological agents used for ≤6 months.[9](#pcn12914-bib-0009){ref-type="ref"}, [10](#pcn12914-bib-0010){ref-type="ref"}, [26](#pcn12914-bib-0026){ref-type="ref"}, [27](#pcn12914-bib-0027){ref-type="ref"}, [28](#pcn12914-bib-0028){ref-type="ref"} Furthermore, the proportion of days with medication intake was 87% (placebo), 75% (nalmefene 10 mg) and 71% (nalmefene 20 mg) in this study compared with 48.0% with nalmefene 20 mg and 63.9% with placebo in ESENSE1,[9](#pcn12914-bib-0009){ref-type="ref"} and 57.0% and 65.2%, respectively, in ESENSE2.[10](#pcn12914-bib-0010){ref-type="ref"} These higher rates may be attributed to the differences in the patient characteristics discussed earlier, along with treatment history, low CIWA‐Ar, better QoL‐related scores and more family/social support observed in the present study. In addition, the majority of the present patients were treatment naïve (\>97%), compared with a considerable proportion of patients in the European studies who received treatment for alcohol dependence. None of the Japanese patients had a history of alcohol withdrawal treatment. From these facts, few patients in the present study experienced failure with alcohol dependence treatment. We also hypothesize that some patients who were seeking better health and life with controlled drinking may be included in the present study.

The present results suggest that the dosing of nalmefene "as needed" was well‐accepted by the patients. Nalmefene can be dosed as needed because it readily occupies μ‐opioid receptors with a high occupancy rate.[29](#pcn12914-bib-0029){ref-type="ref"} When a patient has a desire to drink, taking nalmefene before drinking means that he/she is already conscious of reducing alcohol consumption. This consciousness and patient alignment with treatment goals may also have contributed to the reduction in the number of HDD observed in this study, in addition to the effects of nalmefene. It has been shown that being aligned with treatment goals plays an important role in enhancing the motivation to stay in treatment and in a successful outcome.[30](#pcn12914-bib-0030){ref-type="ref"}, [31](#pcn12914-bib-0031){ref-type="ref"} In fact, clinically meaningful improvements in drinking‐related outcomes are associated with the pre‐treatment drinking goals initially set.[32](#pcn12914-bib-0032){ref-type="ref"} The psychosocial support used in this study aimed at medication adherence with self‐monitoring of alcohol consumption which, in addition to as‐needed treatment, empowers patients to actively participate in treatment decisions. The patient is engaged in treatment by including his/her goal preference in determining treatment options.[33](#pcn12914-bib-0033){ref-type="ref"}

Apart from the reduction in alcohol consumption discussed here, other targets in the management of alcohol dependence include complete abstinence and reduction of craving.[34](#pcn12914-bib-0034){ref-type="ref"} Previous pharmacotherapies, such as naltrexone, acamprosate and disulfiram mainly targeted abstinence and focused on relapse prevention. The present results demonstrate the efficacy and safety of nalmefene in the management of alcohol dependence in patients with a high or very high DRL, suggesting nalmefene as a valuable treatment option for managing heavy drinking in this patient population.

This study had several limitations. First, although fewer patients withdrew from this study than from the previous European studies,[9](#pcn12914-bib-0009){ref-type="ref"}, [10](#pcn12914-bib-0010){ref-type="ref"}, [11](#pcn12914-bib-0011){ref-type="ref"} there were more withdrawals for TEAE in the nalmefene groups than in the placebo group. Therefore, we cannot exclude the possibility of attrition bias. In addition, the MMRM analysis did not include study site as a covariate. Therefore, the possibility of cluster bias cannot be ruled out.

In conclusion, this was the first prospective clinical study to demonstrate the efficacy and safety of nalmefene 20 mg and 10 mg in Japanese patients with a high or very high DRL. Nalmefene may therefore be a valuable pharmacological treatment option for alcohol‐dependent patients who are either not ready or unable to consider complete abstinence as the initial treatment goal, or who have not undergone any treatment; further studies are needed to confirm this.
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